| Q42251464 | Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study |
| Q27010015 | Can antiviral treatment for hepatitis C be safely and effectively delivered in primary care?: a narrative systematic review of the evidence base |
| Q28468297 | Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study |
| Q42259402 | Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. |
| Q41210837 | Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: the ETHOS study |
| Q30429470 | Eligibility of persons who inject drugs for treatment of hepatitis C virus infection |
| Q33862919 | Ending hepatitis C in the United States: the role of screening. |
| Q58782699 | From client to co-worker: a case study of the transition to peer work within a multi-disciplinary hepatitis c treatment team in Toronto, Canada |
| Q41703740 | HCV treatment uptake in people who have injected drugs - observations in a large cohort that received addiction treatment 1970-1984. |
| Q57166986 | Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework |
| Q41534553 | Hepatitis C virus infection and risk factors in the general population: a large community-based study in eastern China, 2011-2012. |
| Q38620824 | Hepatitis C virus-related complications are increasing in women veterans: A national cohort study. |
| Q28550235 | Increased Uptake of HCV Testing through a Community-Based Educational Intervention in Difficult-to-Reach People Who Inject Drugs: Results from the ANRS-AERLI Study |
| Q90067192 | Individual and network factors associated with HCV treatment uptake among people who inject drugs |
| Q38123945 | Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. |
| Q38318678 | Novel interventions to prevent HIV and HCV among persons who inject drugs |
| Q38123947 | Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection |
| Q36353382 | Primary Care-Based Hepatitis C Treatment Outcomes With First-Generation Direct-Acting Agents |
| Q41047662 | Recommendations for the management of hepatitis C virus infection among people who inject drugs |
| Q42955909 | The 3rd Canadian Symposium on Hepatitis C Virus: expanding care in the interferon-free era. |
| Q40959924 | Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study |